VIVUS, Inc (NASDAQ:VVUS)’s shares rose by 7.54% on Friday


Dallas, Texas 11/18/2013 (Financialstrend) – In Friday’s trading session, VIVUS, Inc (NASDAQ:VVUS) rose by 7.54%. The shares opened at a price of $9.15, which touched the intraday high of $9.98 and headed to a close of $9.84. Around 3.30 million exchanged hands over the trading day and an average volume of 2.56 million shares were traded over a 30 day period. The 52-week low of VIVUS, Inc (NASDAQ:VVUS) shares is $8.00 and its 52-week high is $15.62. The company has a market capitalization of $1.00 billion.                                        

About the company

VIVUS, Inc (NASDAQ:VVUS) was incorporated on 16 May 1996. It is a bio-pharmaceutical company. It commercializes & develops various therapies that address unmet-needs in obesity, diabetes, sleep-apnea and sexual health. Qsymia, its drug, is a phentermine & topiramate extended-release formulation. This was approved by the U.S Food and Drug Administration for treatment of obesity as the adjunct to reduced-calorie diet & increased physical-activity for chronic weight-management in adult-patients with an initial BMI of 30 or greater / 27 / greater (overweight) in the presence of at-least 1 weight-related comorbidity, like type 2 diabetes mellitus, hypertension or high cholesterol (dyslipidemia).

Qsymia incorporates low-doses of active ingredients from 2 previously-approved drugs, phentermine & topiramate. VIVUS, Inc (NASDAQ:VVUS) has completed Phase II clinical-studies for Qsymia in the treatment of sleep-apnea. Qsymia is also used for the treatment of type II diabetes. This drug also includes STENDRA / avanafil.

VIVUS, Inc (NASDAQ:VVUS) initially launched Qsymia to be distributed to eligible patients via the home-delivery networks of 2 certified pharmacies, CVS Pharmacy & Walgreens. Since that time, the company has expanded Qsymia’s distribution to include the home-delivery networks of Wal-Mart Pharmacy & Express Scripts, for its members only and Kaiser Permanente. Clinical-studies of topiramate, the component of Qsymia, in type II diabetics resulted in a clinical-reduction of hemoglobin A1c . The Company’s drug, STENDRA, is an oral PDE5-inhibitor that VIVUS, Inc (NASDAQ:VVUS) has now licensed from Mitsubishi Tanabe Pharma Corporation

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.